Table 2:
Distribution of primary and secondary cancer site/histology for 59 cases by cancer sequence
| Cancer Site/Histology | Primary Cancer n (%) | SMN n (%) |
|---|---|---|
| Acute lymphocytic leukemia | 18 (30.5) | 3.3 (2) |
| Acute myeloid leukemia | 1 (1.7) | 15 (25.4) |
| Acute leukemia, mixed phenotypic | 1 (1.7) | 0 (0.0) |
| Hodgkin lymphoma | 3 (5.1) | 0 (0.0) |
| Non-Hodgkin lymphoma | 2 (3.3) | 1 (1.7) |
| Brain glioma | 7 (11.9) | 9 (15.2) |
| Brain ependymoma | 1 (1.7) | 0 (0.0) |
| Medulloblastoma/PNET | 3 (5.1) | 0 (0.0) |
| Neuroblastoma | 4 (5.6) | 0 (0.0) |
| Ewing sarcoma/PNET | 8 (13.6) | 4 (6.8) |
| Osteosarcoma/Malignant fibrous histiosarcoma | 4 (6.8) | 6 (10.1) |
| Soft tissue sarcoma/Rhabdomyosarcoma | 3 (5.1) | 4 (6.8) |
| Wilm’s tumor/Nephroblastoma | 2 (3.3) | 0 (0.0) |
| Renal Cell Carcinoma | 0 (0.0) | 1 (1.7) |
| Renal Papillary Adenocarcinoma | 0 (0.0) | 1 (1.7) |
| Ovarian germ cell tumor | 1 (1.7) | 0 (0.0) |
| Testicular germ cell tumor | 0 (0.0) | 1 (1.7) |
| Retinoblastoma | 1 (1.7) | 0 (0.0) |
| Thyroid | 0 (0.0) | 10 (16.9) |
| Salivary gland carcinoma | 0 (0.0) | 2 (3.3) |
| Melanoma | 0 (0.0) | 1 (1.7) |
| Rectal adenocarcinoma | 0 (0.0) | 1 (1.7) |
| Breast carcinoma | 0 (0.0) | 1 (1.7) |
SMN=second malignant neoplasm; PNET=primitive neuroectodermal tumor.